Last reviewed · How we verify
Doribax (DORIPENEM)
At a glance
| Generic name | DORIPENEM |
|---|---|
| Sponsor | Shionogi |
| Drug class | Penem Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2007 |
Approved indications
- Abdominal abscess
- Cholecystitis
- Complicated Urinary Tract Infections
- Complicated appendicitis
- Infectious disease of abdomen
- Pyelonephritis
Common side effects
Drug interactions
- valproic acid
Key clinical trials
- Antibiotic Concentrations Among Critically Ill Patients
- PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region (PHASE4)
- Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria (PHASE2,PHASE3)
- A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia (PHASE2)
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (PHASE3)
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (PHASE3)
- Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients
- Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |